HomeAI · summaries
Storia in 3 fonti
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to curb the trend before the U.S. loses key biotechnology capabilities. During these discussions, it was only fitting that Pfizer struck an eye-popping development deal with Innovent on 12 cancer meds. And Astellas, facing a key patent cliff, is telling investors how it plans to adapt. Plus more.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercebiotech.com
As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block those deals have gotten louder. | Amid an…
- ·
fiercepharma.com
Cancer is changing. Is pharma marketing changing with it?
Early-onset cancers are rising among adults 18–49, reshaping how patients are diagnosed, supported, and engaged. This report examines key trends, gaps in care, and how data and…
